T-cell death-associated gene 51 (TDAG51) has been described to regulate T-cell receptor/CD3-dependent induction of CD95/ Fas and subsequent activation-induced cell death (AICD) in a murine T-cell hybridoma. Using well-defined pharmacological inhibitors, we investigated the regulation of TDAG51 expression in human T-cells and the correlation with cell death. TDAG51 was induced in resting T-cells, lymphoid cell lines and AICD-susceptible as well as AICD-resistant T-cell clones, and induction was inhibited by MAP-kinase inhibitors and PKC inhibitor Gö 6983. No correlation between the effects of inhibitors on TDAG51 expression and cell death was observed. The constitutive TDAG51 expression in five pancreatic carcinoma cell lines was reduced by MAP-kinase inhibitors but not by Gö 6983. Furthermore, the inducible overexpression of TDAG51 in TetOn Jurkat cells did not modulate cellular proliferation, phorbolester/ionomycin-induced growth arrest, or the expression of various cell surface molecules. Our results indicate that the expression of TDAG51 in human T-cells does not correlate with AICD.
Introduction
Activated but not resting T-cells undergo activation-induced cell death (AICD) when the T-cell receptor (TCR) is triggered via crosslinking of cell surface CD3 or superantigens such as staphylococcal enterotoxins. 1 AICD proceeds through the TCR-mediated upregulation of Fas-ligand (FasL, CD178) and Fas (CD95) expression and subsequent triggering of Fas/ FasL-dependent apoptosis. [2] [3] [4] Despite the upregulation of CD95 following TCR stimulation of resting T-cells, these cells remain AICD-resistant for approximately 6 days, 5 due to the extended presence of FLIP in the death-inducing signalling complex [6] [7] [8] [9] and a block in the mitochondrial apoptosis pathway. 10 While the molecular mechanisms of Fas/FasLtriggered apoptosis have been investigated extensively, 11 it is less clear how CD95 is induced in T-cells follwing TCRmediated antigen recognition or CD3-crosslinking by anti-CD3 monoclonal antibodies (mAb). In this regard, the T-cell death-associated gene 51 (TDAG51) has been isolated by its ability to rescue a murine T-cell hybridoma from its resistance towards AICD after TCR ligation. 12 In these cells, the induction of Fas expression was dependent on the presence of TDAG51, and TDAG51 mRNA was rapidly induced independently of de novo protein biosynthesis. Although these results suggested that TDAG51 is the critical link between AICD and the TCR-mediated upregulation of CD95, T-cells from gene-targeted TDAG51
À/À mice did not suffer from major defects in TCR-mediated CD95 expression or execution of AICD, indicating that TDAG51 is not truly essential for CD95 induction. 13 Rat and human homologues of TDAG51 have been isolated by differential mRNA display approaches. 14, 15 Microinjection of rat TDAG51 cDNA into a neuronal cell line increased CD95-independent cell death, while the microinjection of an anti-TDAG51 antibody prevented differentiation-induced apoptosis.
14 Human TDAG51 was found to be constitutively expressed in benign melanocytic nevi and to be progressively reduced in primary and metastatic melanomas. 15 Taken together, the available evidence suggests that TDAG51 is involved in the regulation of cell growth and cell death, but not necessarily through effects on CD95 expression.
Murine, rat and human TDAG51 share 90% identity on the amino-acid level. Their amino-acid sequence comprises a stretch of glutamines at the N-terminus and a proline/histidinerich repeat, which is directly followed by a proline/glutaminerich repeat at the C-terminus. 12, 14, 15 The human TDAG51 contains two start codons, potentially giving rise to two proteins of 60 kDa (Met 1) and 40 kDa (Met 142), of which only the 40 kDa form seems to get expressed. 15 Furthermore, the human gene contains a potential protein kinase C (PKC) phosphorylation site at position Ser 293. A role of PKC in the regulation of TDAG51 expression was suggested by the observation that phorbolester PMA alone induced TDAG51 mRNA in a murine T-cell hybridoma. 16 In the present study, we have investigated the regulation of TDAG51 expression in human T-cells and pancreatic tumor cells. In order to analyze the impact of TDAG51 expression on T-cell growth and surface antigen expression, we generated inducible Jurkat transfectants using the TetOn system. Our results indicate a role of mitogen-activated protein (MAP) kinases in the inducible and constitutive expression of TDAG51 in human T-cells and tumor cells, but no direct correlation between cell death, AICD, cellular proliferation and the expression of TDAG51 protein.
Results

TDAG51 expression is not restricted to human T-cells
TDAG51 mRNA is ubiquitously expressed in most murine tissues and cell lines. 12 To investigate TDAG51 protein expression in human leukocyte subsets, we tested different Jurkat variants (the parental JE6.1 and the Fas-resistant JM319), EBV-transformed B-lymphoblastoid cell lines, Daudi Burkitt's lymphoma cells and U937 histiocytic lymphoma cells. In all cell lines analyzed, TDAG51 protein was detectable after stimulation with phorbolester PMA plus ionomycin (Figure 1a) . At the level of mRNA, no constitutive expression was detectable in Jurkat JE6.1 cells (Figure 1c 
Time course kinetics of TDAG51 induction in resting human T-cells
Time course experiments with freshly isolated T-cells indicated a rapid TDAG51 protein induction following stimulation with PMA/ionomycin. Protein expression was clearly discernible after 4 h, and peaked after 24 h (Figure 2a ), whereas only a faint band was observed 12 or 24 h after stimulation with immobilized anti-CD3 mAb alone (Figure 2a ). Prolonged time course experiments over 6 days did not reveal an additional increase in protein expression (data not shown). In order to correlate TDAG51 protein induction with the expression of activation markers following T-cell stimulation, we determined the surface expression of CD25, CD69, HLA-DR and CD95 by flow cytometry (Figure 2b ). CD25 induction above basal levels started after 6-8 h and reached a maximum after 48-72 h, with similar kinetics for PMA/ionomycin (Figure 2a , gray bars) and anti-CD3 (Figure 2a , black bars) stimulation. CD69 was rapidly induced by PMA/ionomycin with maximal expression after 4-6 h, whereas delayed CD69 expression was induced by anti-CD3 stimulation. HLA-DR, a known 'late' activation marker of human T-cells, was not detectable before 72 h following stimulation. Induction of CD95 started 24 h after stimulation, and reached peak levels after 72 h stimulation with PMA/ionomycin or anti-CD3 mAb. These results indicate Next, we investigated the effect of well-characterized inhibitors of the MAP kinase and protein kinase C (PKC) pathways on the induction of CD95 and TDAG51 expression in freshly isolated T-cells. As shown in Figure 3a , the MAPkinase inhibitor U0126 suppressed the TDAG51 induction by anti-CD3/anti-CD28 mAb crosslinking, and PKC inhibitor Gö 6981 inhibited TDAG51 induction by both anti-CD3/anti-CD28 and PMA/ionomycin stimulation. Both inhibitors exerted similar inhibitory effects on the anti-CD3/anti-CD28-stimulated induction of CD95 on freshly isolated T-cells (Figure 3b ), indicating that both TDAG51 and CD95 induction are regulated by MAP kinases and PKC.
TDAG51 expression in T-cell clones is regulated by MAP kinases and PKC and does not correlate with cell death
We have previously characterized AICD-sensitive and AICDresistant IL-2-dependent human T-cell clones which did not differ in their CD95 expression. 17 As shown in Figure 4a , TDAG51 protein expression was readily induced in the AICDsensitive T-cell clone D798/18 but also in the AICD-resistant clone D566/4. Stimulation with PMA or PMA/ionomycin for 6 h induced a stronger protein expression than immobilized anti-CD3 mAb, while crosslinking with anti-CD4 mAb did not induce TDAG51 expression (Figure 4a) . We also tested different MAP-kinase inhibitors (U0126, PD98059, SB203580), which block downstream events of the Ras/Raf signaling pathway, the PKC inhibitor Gö 6983, src-kinase inhibitor herbimycin A, PI3-kinase inhibitor wortmannin and FK506, which blocks calcium/calmodulin-dependent kinases, for their effects on the regulation of TDAG51 protein expression in these clones. In a representative experiment depicted in Figure 4b 
TDAG51 protein expression in tumor cells is regulated by MAP kinases
To investigate whether MAP kinases are also involved in the constitutive expression of TDAG51 in different Ras-mutated tumor cell lines, we supplemented the culture medium with the ERK1/2 inhibitors U0126 and PD98059 and the p38 MAP kinase inhibitor SB203580 either individually or in different combinations repeatedly four times to the cultures, as described in detail in 'Materials and Methods'. As shown in Figure 6a and b, the ERK1/2 inhibitors U0126 and PD98059 reduced the constitutive TDAG51 protein expression in all pancreas carcinoma cell lines, whereas the PKC inhibitor Gö 6983 at 5 mM did not have a significant effect, and SB203580 showed only a weak reduction of TDAG51 expression. In contrast to the inducible TDAG51 expression in T-cells ( Figure 4 , Table 1 ), there was no synergistic inhibitory effect when the different MAP kinase inhibitors were combined with Gö 6983. In this case, the reduced TDAG51 expression was comparable to that seen when tumor cells were incubated with MAP kinase inhibitors alone (Figure 6a ).
Inducible TDAG51 expression in TetOn Jurkat cells does not influence cell proliferation
As shown above, TDAG51 is constitutively expressed in tumor cells of epithelial origin, and is inducibly expressed in lymphoid cells. To directly investigate the possible effects of TDAG51 expression in T-cells, we used the TetOn system to generate inducible Jurkat lines which were transfected with the empty TRE vector or the TDAG51-containing vector. The induction of TDAG51 by doxycycline (Doxy) in this TetOn Jurkat lines is shown in Figure 7a . As can be seen, TDAG51 (Figure 7b, lower panel) . We also analyzed by flow cytometry the effect of TDAG51 overexpression on the expression of different surface molecules such as CD2, CD3, CD4, TCRab, MHC I, CD28, activation markers, molecules of the TNF receptor family, chemokine receptors and adhesion molecules. As summarized in Table 2 , there was no significant difference in the expression of all analyzed surface molecules between the parental TetOn Jurkat line as compared to the TetOn TRE line or the TetOn TDAG line with/without Doxy. Moreover, TDAG51 overexpression did not influence the effects of PMA/ionomycin stimulation on cell surface marker expression. Finally, we also analyzed protein tyrosine and Figure 4 Correlation between TDAG51 protein expression and cell death. T-cell clones D798/18 (AICD-sensitive) and D566/4 (AICD-resistant) were cultured in medium alone (control) or in the presence of PMA, ionomycin, a combination of PMA and ionomycin, immobilized or soluble anti-CD3 or anti-CD4 mAb for 5 h. TDAG51 expression in cell lysates was determined using the polyclonal anti-TDAG51 antibody L-19 (a). T-cell clones D798/18 (b, d) and D596/6 (AICD-resistant; c, e) were stimulated with PMA/ionomycin (b, c) or anti-CD3 mAb OKT3 (d, e). ERK1/2 inhibitors U0126 (U), PD98059 (PD), p38 MAP kinase inhibitor SB203580 (SB) and PKC inhibitor Gö6983 (Gö) alone or in combination, src-kinase inhibitor herbimycin A (HerbA), PI3-kinase inhibitor wortmannin (Wort) or FK506 were applied 1 h before stimulation, as described in Materials and Methods. The DMSO solvent control contained 0.5% DMSO, equivalent to the highest DMSO concentration present in any of the inhibitors. After 5 h, TDAG51 expression in cell lysates was determined using the PHLDA-1 mAb. The membranes were stripped and reprobed with anti-b-actin mAb to control for the loading and transfer, as described in Materials and Methods. Cell death was measured after 20 h by flow cytometry analysis of propidium iodide-positive cells. One representative (out of four) experiments is shown ERK1/2 phosphorylation after stimulation with PMA/ionomycin or crosslinking of CD3, but did not detect significant differences upon TDAG51 induction in TetOn Jurkat cells as compared to empty vector transfectants (data not shown). 12 by differential cDNA library screening of an AICD-sensitive mouse T-cell hybridoma and a mutant that was resistant to AICD mediated via CD3/TCR stimulation, but susceptible to cell death triggered by dexamethasone. Transfection of TDAG51 into the mutant T-cell hybridoma restored anti-CD3 mAb-induced CD95 expression and AICD, suggesting that TDAG51 played an essential role in the induction of apoptosis by coupling TCR stimulation to CD95 expression. This view, however, has been challenged by the observation that T-cells from TDAG51 À/À mice do not display discernible defects in CD3/ TCR-dependent upregulation of CD95 expression or AICD. 13 Since there are several pleckstrin-homology domain-containing proteins with significant homology to TDAG51, [18] [19] [20] [21] it might be possible that one of these homologues fulfills the role ascribed to TDAG51 in normal murine and human T-cells. In line with a dispensable role of TDAG51 in the regulation of AICD, we did not observe a correlation between TDAG51 expression and the induction of AICD in a set of AICDsusceptible and AICD-resistant human T-cell clones. Other reports, however, support a role for TDAG51 in the initiation of cell death. The rat homologue of TDAG51 was thus found to enhance cell death upon microinjection of the corresponding cDNA into a neuronal cell line, and microinjection of an anti-TDAG51 antibody increased cell survival. 14 More recently, TDAG51 was also implied in the regulation of programmed cell death in human vascular endothelial cells triggered by homocysteine. As reported by Hossain et al, 22 transient overexpression of TDAG51 in vascular endothelial cells elicited changes in cell morphology, decreased cell adherence and promoted apoptosis. Moreover, these authors observed that phosphorylation of the translation initiation factor eIF2a was required for transcriptional activation of TDAG51. 22 This is of considerable interest, as we have previously identified the p66 subunit of the eukaryotic translation initiation factor eIF3 as a binding partner of human TDAG51 in a yeast-two-hybrid screen. 23 In a luciferase reporter assay, we observed significant inhibition of protein synthesis upon transient cotransfection of TDAG51, suggesting that one role of TDAG51 might be a regulatory impact on protein synthesis. 23 While the precise function of TDAG51 under physiological and pathophysiological conditions is thus still unclear, the rapidly inducible expression in lymphoid cells together with the constitutive expression in epithelial tumor cells and the reported involvement in cell death control at least in certain cell types, all point to an important role in the regulation of cell growth and differentiation. Using well-characterized inhibitors of various signaling pathways, we have compared the inducible expression of TDAG51 in human T-cells with the constitutive expression in pancreatic tumor cells. TDAG51 protein was rapidly induced within 4 h in resting T-cells by PMA/ionomycin, and was further upregulated within 24 h. While CD3 crosslinking by immobilized anti-CD3 mAb alone was less effective, the combined stimulation with anti-CD3 plus anti-CD28 mAb resulted in efficient TDAG51 induction. The rapid induction of TDAG51 protein correlated well in time with the rapid induction of the activation antigen CD69, which reached almost maximal levels already 4 h after PMA/ionomycin stimulation (see Figure 2) . On the other hand, TDAG51 protein expression clearly preceded the induction of cell surface expression of CD95 and of late activation antigens such as CD25 and HLA-DR. The induction of TDAG51 in human T-cell clones and freshly isolated T-cells was inhibited by MAP kinase inhibitors and by the PKC inhibitor Gö 6983, suggesting that both pathways are involved in the induction of TDAG51 in T-cells. A role for PKC in the induction of TDAG51 was previously suggested based on the observation that the known PKC activator PMA alone induced TDAG51 mRNA expression in a murine T-cell hybridoma. 16 While ERK1/2 inhibitor U0126 alone inhibited TDAG51 induction in T-cells (Figures 3 and 4 , and Table 1), the inhibitory effect was strongly enhanced when PKC was simultaneously inhibited by Figure 6 Inhibition of hTDAG51 protein expression in tumor cells. ERK1/2 inhibitors U0126, PD98059, p38 MAP kinase inhibitor SB203580 and PKC inhibitor Gö6983 alone or in combination were applied to cultures of Capan-1 pancreatic tumor cell line, as described in Materials and Methods (a). An additional four tumor cell lines were treated with U0126 or Gö6983 (b). After 40 h, hTDAG51 expression in lysates was determined using the polyclonal anti-TDAG51 antibody L-19. This experiment is representative of three experiments Gö 6983. A synergistic effect was also observed when Gö 6983 was combined with the other MAP kinase inhibitors PD98059 and SB203580, while the latter two were less effective than U0126 when applied alone. Taken together, these results indicate that the efficient induction of TDAG51 expression in human T-cells requires the PKC and the RasRaf-MEK-ERK signaling pathways. We also used the inhibitors to dissect the induction of cell death and expression of CD95 and the regulation of TDAG51 expression in freshly isolated T-cells and T-cell clones, but did not observe a clear correlation. Although the combination of MAP kinase inhibitors and Gö 6983 strongly inhibited TDAG51 induction in response to PMA/ionomycin, they had only marginal effects on subsequent cell death. The combined MAP kinase and PKC inhibitors always suppressed TDAG51 induction following CD3 crosslinking, independently of whether AICD was (clone D798/18; Figure 4D ) or was not (clone D596/6; Figure 4E ) induced by anti-CD3 mAb. Collectively, our experiments with clonally defined human T-cells support the conclusion from studies with TDAG51 À/À mice that -in contrast to the original assumption 12 -TDAG51 is not involved in the regulation of AICD.
Discussion
We found that TDAG51 was constitutively expressed at the protein level in a variety of pancreatic tumor cell lines expressing a mutated form of Ras, as well as in several pancreas tumor samples. The constitutive expression of TDAG51 protein in the tumor lines was drastically reduced by ERK1/2 inhibitor U0126, while p38 MAP kinase inhibitor SB203580 was less efficient. Interestingly, no reduction of constitutive TDAG51 protein expression was observed when the tumor cells were cultured in the continuous presence of Gö 6983, indicating that -in contrast to the inducible expression in T-cells -PKC is not involved in the constitutive expression of TDAG51 in tumor cells. These results suggest that the mutated Ras might regulate the constitutive TDAG51 expression via the MAP-kinase signaling pathway. In a recent study, Neef et al. 15 identified human TDAG51 (which they termed PHLDA1 for pleckstrin-homology-like domain family A, member 1) by a differential mRNA display between primary and metastatic melanoma cells as a gene that was downregulated in metastatic as compared to primary melanoma. TDAG51 protein was expressed by benign melanocytic nevi, but not in epidermal melanocytes. These authors also established stable TDAG51 transfectants of 293 cells and Mel Rif, a melanoma cell line, and they observed reduced growth rates of the transfectants but no alterations in the expression of a variety of cell surface molecules. Moreover, the stable transfectants displayed slightly increased rates of basal apoptosis, and increased sensitivity to chemotherapeutic drugs. 15 While these results suggested that TDAG51 is involved in the regulation of cell growth and apoptosis, it is premature to draw definitive conclusions. Thus, despite massive TDAG51 protein expression, some of the presently analyzed pancreatic tumor cells are largely resistant to apoptosis and chemotherapeutic agents. 24 Moreover, we did not observe any change in the growth pattern of our TetOn Jurkat transfectants upon inducible expression of TDAG51 protein. Despite high-level TDAG51 protein expression, there was no increased sensitivity to apoptosis when compared to non-induced or control vector-transfected TetOn Jurkats.
Although the precise function of TDAG51 remains to be defined, our results provide new insights into the signaling pathways involved in the inducible and constitutive expression in T-lymphocytes and tumor cells, respectively. Since TDAG51 À/À mice do not have obvious abnormalities in the lymphoid compartment and do not suffer from disturbed T-cell apoptosis, 13 it is possible that certain functions of TDAG51 are 
18-21
Materials and Methods
Isolation of T-cells and culture of T-cell clones and tumor cell lines
Peripheral blood mononuclear cells (PBMC) were isolated by FicollHypaque density gradient centrifugation from buffy coats obtained from healthy blood donors. PBMC were separated into T-cells and non-T-cells by rosetting with neuraminidase-treated sheep erythrocytes and subsequent density gradient centrifugation. Resting T-cells were cultured in complete medium (CM) consisting of RPMI 1640 with 10% (v/v) FCS (Invitrogen/LifeTechnologies, Karlsruhe, Germany), antibiotics (penicillin at 100 U/ml and streptomycin at 100 mg/ml), L-glutamine (2 mM) and HEPES buffer solution (25 mM) at 371C in a humidified atmosphere with 5% CO 2 . The CD4 þ human T-cell clones established from healthy donors have been described, 17 and were cultured in CM as described above. Clones were restimulated periodically with irradiated PBMC and EBVtransformed lymphoblastoid cell lines in the presence of PHA (0.5 mg/ml, Murex Biotech Ltd., Dartford, England). At 3-5 days after restimulation, dead cells were removed by centrifugation on Ficoll-Hypaque density gradients. The clone cells were washed and expanded in the presence of 50 U/ml rIL-2 (sp. Act., 18 Â 10 6 U/mg, Chiron Behring, Marburg, Germany) for at least 10 days before use in the assay. The pancreatic carcinoma cell lines Panc-1, CFPAC-1, Capan-1, BxPC3, Colo357, PancTu-1, PT45P1 bearing a mutated form of Ras were cultured in CM.
Detection of TDAG51 protein by Western blot analysis
Cells were pelleted, washed in PBS and lysed in 50 ml of Nonidet P40 (Fluka Chemie, Buchs, Switzerland) lysis buffer (1% (v/v) of detergent in 20 mM Tris-HCl (pH 8.1), 150 mM NaCl with protease inhibitors aprotinin, leupeptin, phenyl methyl sulfonyl fluoride, sodium pyrophosphate and sodium fluoride). Lysates remained on ice for 15-30 min before centrifugation at 41C and 14 000 rpm for 10 min. The protein content of supernatants was determined by Coomassie Protein Assay Reagent (Pierce, Rockford, IL, U.S.A.) and adjusted to 50-80 mg total protein/lane. Samples were boiled in reducing sample buffer with b-mercaptoethanol, separated on 10% SDS-polyacrylamide gels, and protein was transferred to nitrocellulose membranes (Hybond C-Extra, Amersham, Braunschweig, Germany). Blots were blocked with 5% BSA (Sigma-Aldrich, Taufkirchen, Germany) and TDAG51 protein was detected with purified mAb PHLDA-1 15 (a gift from Dr. J Johnson, Munich) or polyclonal Ab L-19 (Santa Cruz, Santa Cruz, CA, USA), followed by HRP-conjugated sheep anti-mouse (Amersham) or bovine anti-goat (Santa Cruz) Ab and chemiluminescence detection reagent (ECL, Amersham). As a control of loading and transfer, membranes were stripped (62.5 mM Tris-HCl pH 6.8; 100 mM b-mercaptoethanol, 2% SDS) for 30 min at 561C and reprobed with anti-b-actin mAb (A5441 from Sigma). b-actin bands were quantified by the Quantity One software (Biorad; Munich) to normalize the TDAG51 protein expression to the overall protein content.
RT-PCR of TDAG51
TDAG51 mRNA was analyzed using a PCR approach based on total RNA. 3 Â 10 6 cells were incubated in CM in the absence or presence of agents for the time periods detailed in Results section. The cells were then washed in cold PBS and total RNA was isolated using the Qiagen RNeasyt Total RNA Kit (Qiagen, Hilden, Germany). The RNA was quantified, and aliquots of 0.5 mg/sample were subjected to RT-PCR using RNA PCR kit from Perkin-Elmer (Roche Molecular Systems, Branchburg, NJ, USA). The following oligonucleotide primers were used: for human TDAG51: sense 5 0 -ATA-AGG-ATC-CCT-GGA-GAG-TAG-CGG-CTG-C-3 0 and antisense 5 0 -ATA-AGA-ATT-CTC-AGG-CAG-AGT-TGG-AGG-T-3 0 (Eurogentec, Cologne, Germany) to yield the complete 797 bp sequence. PCR was performed with 35 cycles and an annealing temperature of 621C for TDAG51. PCR products were analyzed following separation by electrophoresis in 1% agarose gel.
Immunohistochemistry
Normal and ductal pancreatic carcinoma tissues were removed freshly from resection specimens according to the permission of the local ethical committee (permission number 110/99). Samples were snap frozen in a mixture of isopentane and dry ice and stored at À801C. For immunostaining, 5 mm cryosections were cut, dried and fixed in acetone for 10 min. Fixed frozen sections were incubated with 0.03% hydrogenperoxidase for 2 Â 20 min. Intrinsic avidin and biotin were blocked with avidin-biotin-blocking kit from Vector Laboratories (Burlingame, CA, USA). Serum blocking and detection were performed with peroxidasebased mouse Vectastain Kit (Vector Laboratories, Burlingame, CA, USA) according to the instructions. The primary antibody was anti-TDAG51 mAb PHLDA-1 applied at 5 mg/ml concentration. As a negative control, the primary antibody was replaced by mouse IgG1 (DAKO, Hamburg, Germany) in the same concentration.
Flow cytometry
5-10 Â 10 4 T-cells or TetOn Jurkat cells were washed twice with washing buffer (1% BSA/PBS) and incubated with primary mAb for 20 min at 41C. Thereafter, the cells were washed twice. Unconjugated or biotinylated primary mAb were detected by second-step reagents, that is, PEconjugated goat F(ab 0 ) 2 anti-mouse Ab (Caltag, Burlingame, CA, USA) or PE-conjugated streptavidin (Streptavidin-PE; BD Biosciences), respectively. The cells were incubated for 20 min with second step reagents, washed twice, and fixed in 100 ml 1% paraformaldehyde/PBS. We used the following mAb as PE-conjugates: CD2, CD3, CD4, CD11a, CD25, CD28, CD45RO, CD69, CD95, HLA-DR (MHC II), TNF-R I (all from BD Biosciences, Heidelberg, Germany) and chemokine receptor mAb CXCR3 (R&D Systems, Wiesbaden, Germany). The following mAb were used as FITC-conjugates: TCRab, CD11a, CD45RA, CD18 (all from BD Biosciences, Heidelberg, Germany) and w6/32 (MHC I). In addition, we used biotin-conjugated CD134 mAb (BD Biosciences) and unconjugated CXCR4 mAb (R&D). Appropriate fluorochrome-labeled isotype controls were included. All analyses were measured on a FACScan flow cytometer using the CellQuest software (Becton Dickinson). Results are presented as the median fluorescence intensity (MFI).
Inhibition of TDAG51 expression in T-cells and tumor cells
The following inhibitors were used: MAP kinase kinase inhibitors U0126 (10 mg/ml), PD98059 (40 mg/ml), p38 MAP kinase inhibitor SB203580 (40 mg/ml), [25] [26] [27] which block downstream events of the Ras/Raf pathway, PKC inhibitor Gö6983 (5 mg/ml), 28 src-kinase inhibitor Herbimycin A (1.5 mM), 29 PI3-kinase inhibitor Wortmannin (100 nM) 30 and FK506
(10 ng/ml), 31 which blocks calcium/calmodulin-dependent kinases. All inhibitors were obtained from Calbiochem (Calbiochem-Novabiochem, Bad Soden, Germany) and were disolved in DMSO. The highest concentration of DMSO used in the experiments per se did not show any effect on cell death or TDAG51 protein expression. The optimal working concentration of each inhibitor was initially determined on Jurkat cells and T-cell clones. 1.5 Â 10 6 T-cells were pretreated for 1 h with different inhibitors before stimulation with a combination of PMA (10 ng/ml, Sigma) and ionomycin (500 ng/ml, Calbiochem), immobilized anti-CD3 mAb OKT3 (10 mg/ml, Orthoclone) in the absence or presence of anti-CD28 mAb (5 mg/ml, clone CD28.2, BD Biosciences), a combination of staphylococcal enterotoxin A and E (SEA/SEE; 1 ng/ml each, Serva), or PHA (1 mg/ml). Cells were pelleted, lysed and analyzed after 5, 12 or 20 h of stimulation by Western blotting. Tumor cells were cultured in CM for 24 h before inhibitors were added. MAP-kinase inhibitors alone, in combination with Gö6983 or Gö6983 alone, were added 40, 24, 14 and 6 h before Western blot analysis. To avoid the toxic accumulation of DMSO, the medium was exchanged at each time point and supplemented with the different freshly prepared inhibitors in final concentrations as indicated above. Cells were lysed and blotted as described above.
